{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T14:01:40Z","timestamp":1762956100417,"version":"build-2065373602"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T00:00:00Z","timestamp":1554422400000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","award":["CIRPD3B0013","CLRPD190019","CMRPD1H0251","CRRPD1F0053"],"award-info":[{"award-number":["CIRPD3B0013","CLRPD190019","CMRPD1H0251","CRRPD1F0053"]}],"id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002836","name":"Chang Gung University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002836","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["106-2632-B-182-002","MOST 106-2320-B-182-029-MY3"],"award-info":[{"award-number":["106-2632-B-182-002","MOST 106-2320-B-182-029-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital, Linkou","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedical Journal"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.bj.2019.03.004","type":"journal-article","created":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T09:07:19Z","timestamp":1556615239000},"page":"80-83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["From discovery of tyrosine phosphorylation to targeted cancer therapies: The 2018 Tang Prize in Biopharmaceutical Science"],"prefix":"10.1016","volume":"42","author":[{"given":"Jau-Song","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bj.2019.03.004_bib1","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.bj.2019.03.004_bib2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10540-005-2846-0","article-title":"Phosphoproteome analysis","volume":"25","author":"Raggiaschi","year":"2005","journal-title":"Biosci Rep"},{"key":"10.1016\/j.bj.2019.03.004_bib3","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1001\/jama.1989.03430130091040","article-title":"The Albert Lasker Medical Awards. Role of the cyclic AMP-dependent protein kinase in signal transduction","volume":"262","author":"Krebs","year":"1989","journal-title":"JAMA"},{"key":"10.1016\/j.bj.2019.03.004_bib4","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/0092-8674(79)90205-8","article-title":"An activity phosphorylating tyrosine in polyoma T antigen immunoprecipitates","volume":"18","author":"Eckhart","year":"1979","journal-title":"Cell"},{"key":"10.1016\/j.bj.2019.03.004_bib5","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1073\/pnas.77.3.1311","article-title":"Transforming gene product of Rous sarcoma virus phosphorylates tyrosine","volume":"77","author":"Hunter","year":"1980","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bj.2019.03.004_bib6","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/0092-8674(81)90100-8","article-title":"Epidermal growth factor induces rapid tyrosine phosphorylation of proteins in A431human tumor cells","volume":"24","author":"Hunter","year":"1981","journal-title":"Cell"},{"key":"10.1016\/j.bj.2019.03.004_bib7","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/290516a0","article-title":"Purified EGF receptor-kinase interacts specifically with antibodies to Rous sarcoma virus transforming protein","volume":"290","author":"Chinkers","year":"1981","journal-title":"Nature"},{"key":"10.1016\/j.bj.2019.03.004_bib8","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/307521a0","article-title":"Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences","volume":"307","author":"Downward","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.bj.2019.03.004_bib9","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1126\/science.6326261","article-title":"Expression cloning of human EGF receptor complementary DNA: gene amplification and three related messenger RNA products in A431 cells","volume":"224","author":"Lin","year":"1984","journal-title":"Science"},{"key":"10.1016\/j.bj.2019.03.004_bib10","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/0092-8674(80)90327-X","article-title":"Evidence that the phosphorylation of tyrosine is essential for cellular transformation by Rous sarcoma virus","volume":"20","author":"Sefton","year":"1980","journal-title":"Cell"},{"key":"10.1016\/j.bj.2019.03.004_bib11","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/0092-8674(84)90438-0","article-title":"An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity","volume":"37","author":"Konopka","year":"1984","journal-title":"Cell"},{"key":"10.1016\/j.bj.2019.03.004_bib12","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1126\/science.3460176","article-title":"The chronic myelogenous leukemia-specific P210 protein is the product of the bcr\/abl hybrid gene","volume":"233","author":"Ben-Neriah","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.bj.2019.03.004_bib13","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.bj.2019.03.004_bib14","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/j.1460-2075.1990.tb08212.x","article-title":"Bcr-Abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice","volume":"9","author":"Elefanty","year":"1990","journal-title":"EMBO J"},{"key":"10.1016\/j.bj.2019.03.004_bib15","doi-asserted-by":"crossref","first-page":"6649","DOI":"10.1073\/pnas.87.17.6649","article-title":"Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR\/ABL","volume":"87","author":"Kelliher","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bj.2019.03.004_bib16","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/344251a0","article-title":"Acute leukaemia in bcr\/abl transgenic mice","volume":"344","author":"Heisterkamp","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.bj.2019.03.004_bib17","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1126\/science.279.5350.577","article-title":"Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors","volume":"279","author":"Hirota","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.bj.2019.03.004_bib18","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/1209","article-title":"Familial gastrointestinal stromal tumours with germline mutation of the KIT gene","volume":"19","author":"Nishida","year":"1998","journal-title":"Nat Genet"},{"key":"10.1016\/j.bj.2019.03.004_bib19","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bj.2019.03.004_bib20","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.bj.2019.03.004_bib21","doi-asserted-by":"crossref","first-page":"13306","DOI":"10.1073\/pnas.0405220101","article-title":"EGF receptor gene mutations are common in lung cancers from \u2018\u2018never smokers\u2019\u2019 and are associated with sensitivity of tumors to gefitinib and erlotinib","volume":"101","author":"Pao","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bj.2019.03.004_bib22","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.bj.2019.03.004_bib23","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","article-title":"Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer","volume":"244","author":"Slamon","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.bj.2019.03.004_bib24","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1200\/JCO.1992.10.7.1044","article-title":"Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up","volume":"10","author":"Toikkanen","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bj.2019.03.004_bib25","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1126\/science.3263702","article-title":"Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors","volume":"242","author":"Yaish","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.bj.2019.03.004_bib26","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1016\/S0021-9258(18)42864-5","article-title":"Selective interactions of transforming and normal abl proteins with ATP, tyrosine-copolymer substrates, and tyrphostins","volume":"267","author":"Anafi","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bj.2019.03.004_bib27","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.1182\/blood.V82.12.3524.3524","article-title":"Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity induces K562 to differentiate","volume":"82","author":"Anafi","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.bj.2019.03.004_bib28","first-page":"100","article-title":"Inhibition of the Abl protein-tyrosine kinase in\u00a0vitro and in\u00a0vivo by a 2-phenylaminopyrimidine derivative","volume":"56","author":"Buchdunger","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.bj.2019.03.004_bib29","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.bj.2019.03.004_bib30","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1182\/blood.V90.12.4947","article-title":"CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins","volume":"90","author":"Carroll","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bj.2019.03.004_bib31","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"Engl J Med"},{"key":"10.1016\/j.bj.2019.03.004_bib32","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bj.2019.03.004_bib33","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bj.2019.03.004_bib34","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-3565(24)38879-2","article-title":"Abl protein-tyrosine kinase inhibitor STI571 inhibits in\u00a0vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors","volume":"295","author":"Buchdunger","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bj.2019.03.004_bib35","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors","volume":"347","author":"Demetri","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bj.2019.03.004_bib36","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1073\/pnas.80.5.1337","article-title":"Growth stimulation of A431 cells by EGF: identification of high affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody","volume":"80","author":"Kawamoto","year":"1983","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bj.2019.03.004_bib37","first-page":"1002","article-title":"Growth inhibition of human tumor cells in athymic mice by anti-EGF receptor monoclonal antibodies","volume":"44","author":"Masui","year":"1984","journal-title":"Cancer Res"},{"key":"10.1016\/j.bj.2019.03.004_bib38","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/1078-0432.CCR-14-2491","article-title":"CCR 20th anniversary commentary: a chimeric antibody, C225, inhibits EGFR activation and tumor growth","volume":"21","author":"Mendelsohn","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bj.2019.03.004_bib39","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/jnci\/83.2.97","article-title":"Phase I imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma","volume":"83","author":"Divgi","year":"1991","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.bj.2019.03.004_bib40","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bj.2019.03.004_bib41","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bj.2019.03.004_bib42","first-page":"e553","article-title":"Overview of FDA-approved anti-cancer drugs used for targeted therapy","volume":"2","author":"Di Martino","year":"2015","journal-title":"WCRJ"},{"key":"10.1016\/j.bj.2019.03.004_bib43","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1172\/JCI31691","article-title":"Treatment for chronic myelogenous leukemia: the long road to imatinib","volume":"117","author":"Hunter","year":"2007","journal-title":"J Clin Investig"}],"container-title":["Biomedical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2319417019301040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2319417019301040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:06:10Z","timestamp":1762419970000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2319417019301040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S2319417019301040"],"URL":"https:\/\/doi.org\/10.1016\/j.bj.2019.03.004","relation":{},"ISSN":["2319-4170"],"issn-type":[{"type":"print","value":"2319-4170"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From discovery of tyrosine phosphorylation to targeted cancer therapies: The 2018 Tang Prize in Biopharmaceutical Science","name":"articletitle","label":"Article Title"},{"value":"Biomedical Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bj.2019.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Chang Gung University. Publishing services by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}